ArticleFrontiers in physiology2025
Case Report: From multimodality imaging to catheter ablation of ventricular arrhythmias in arrhythmogenic mitral valve prolapse.
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mitral valve prolapse (MVP) is a common condition, typically benign, but in a small subset of patients, it may lead to life-threatening arrhythmias and sudden cardiac death (SCD). This arrhythmogenic MVP phenotype is often associated with bileaflet prolapse, mitral annular disjunction (MAD), and myocardial fibrosis identified via late gadolinium enhancement (LGE) on cardiac MRI. Case Summary: Our patient is a 49-year-old man presented with monomorphic ventricular tachycardia and near-syncope. Echocardiography showed bileaflet MVP, MAD and mild mitral regurgitation. Cardiac MRI revealed fibrosis in the papillary muscle. Electrophysiological study (EPS) confirmed inducible ventricular fibrillation (VF) triggered by papillary muscle PVCs. Catheter ablation was successfully performed, eliminating the arrhythmic focus. Despite successful ablation, an implantable cardioverter-defibrillator (ICD) was implanted for secondary prevention, given the high-risk structural substrate. The patient remained arrhythmia-free over 2 years of follow-up. Discussion: This case highlights critical diagnostic markers-bileaflet prolapse and LGE-associated with arrhythmogenic MVP. While ablation may suppress triggers, it does not completely eliminate the underlying substrate. Current expert consensus supports ICD implantation in patients with sustained VT/VF or sudden cardiac arrest, regardless of ablation success. Management should be individualized based on risk profile, imaging findings, and clinical presentation. Conclusion: Malignant MVP warrants comprehensive evaluation with echocardiography, cardiac MRI, and EPS. Catheter ablation is effective in eliminating arrhythmic foci, but ICD therapy remains essential for secondary prevention. Future high-quality trials and clear guidelines for diagnosis, risk stratification, and management are essential to avoid both over- and under-treatment, ensuring optimal outcomes for the patients with MVP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.